Stayble has now enrolled and treated the first patient in the company's clinical phase Ib study with STA363 for the treatment of herniated discs. This milestone marks a continued positive development for the drug candidate STA363, which is already undergoing a phase IIb study for degenerative disc disease.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.478 SEK | +6.70% |
|
+45.73% | +57.76% |
1st Jan change | Capi. | |
---|---|---|
+57.76% | 1.36M | |
+20.95% | 127B | |
+23.00% | 117B | |
+25.47% | 27.77B | |
-19.75% | 20.44B | |
-15.59% | 16.62B | |
-16.56% | 15.92B | |
+11.19% | 14.74B | |
-46.65% | 14.94B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- STABL Stock
- News Stayble Therapeutics AB
- Stayble Enters the First Patient in Herniated Disc Study